Abstract:To determine the role of hepatitis C virus (HCV) genotype 1 b genetic variation in the open reading frame for treatment outcomes of the pegylated-interferon/ribavirin (peg-IFN/RBV) combination therapy by examining patients from Henan Province with chronic hepatitis C (CHC).Thirty-seven treatment naive patients infected with HCV genotype 1b were included in the study. Prior to initiation of a 48-week course of peg-IFN/RBV therapy, peripheral blood was drawn for sequencing of the viral ORF 5'-half. Patients were assessed at the end of the 48 weeks of treatment and at a 6-month follow-up appointment. The patient data was stratified according to the status of sustained viral response (SVR) group and non-response (NR) and statistical analysis was performed to determine the correlation between detected genetic variations and treatment response status.Genetic variability in the ORF 5'-half was significantly higher among the individuals in the SVR group than among those of the NR group. Significant differences were found in the gene regions encoding p7, NS2 and NS3. For p7, the NR group had actual and expected frequencies of special mutation of 9.0 and 17.4 and total mutation of 77.0 and 68.6, while the SVR group had actual and expected frequencies of special mutation of 42.0 and 33.6 and total mutation of 124.0 and 132.4 (x2 =7.725, P =0.05). For NS2, the NR group had actual and expected frequencies of special mutation of 36.0 and 54.3 and total mutation of 270.0 and 251.7, while the SVR group had actual and expected frequencies of special mutation of 106.0 and 87.7 and total mutation of 388.0 and 406.3 (x2 = 12.16, P less than 0.01). For NS3, the NR group had actual and expected frequencies of special mutation of 49.0 and 53.4 and total mutation of 241.0 and 236.6, while the SVR group had actual and expected frequencies of special mutation of 81.0 and 76.6 and total mutation of 335.0 and 339.4 (x2 =6.745, P =0.043). The inter-patient genetic variations in the NS3 gene were concentrated in the protease domain. Furthermore, there was a strong correlation between HCV diversity in p7 and treatment outcome.The genetic data reported here provides strong support for the role of NS2, NS3 and p7 in antagonizing the peg-IFN/RBV response during the treatment of HCV infections. We conclude that higher inter-patient viral genetic diversity correlates with successful treatment and may modulate the efficacy of antiviral therapy in CHC patients of Henan.

[Variation in Hepatitis C Virus NS 5b Nucleotide Sequence and Its Relationship with Interferon Treatment].

Interaction Between Variability of Nonstructural Gene5b of Hepatitis C Virus and Interferon Therapy

Genetic Variability and Characterization of Non-Structural Region 5 of Hepatitis C Virus Genome from Chinese Patients

Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up

Association Between NS5A Gene Sequence and Response to Interferon Therapy in Chronic Hepatitis C Patients in Shanghai

Study of genetic variation of the structural region of hepatitis C virus

Genetic Variation Characteristics of the Envelope Region of Hepatitis C Virus in the Patients with Chronic Hepatitis

Sequence Diversity of Hepatitis C Virus 6a Within the Extended Interferon Sensitivity-Determining Region Correlates with Interferon-Alpha/ribavirin Treatment Outcomes

Genetic variation of the core and E1 region of hepatitis C virus in serum collected from patients with chronic hepatitis

Mutations in the NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon alpha-2a and ribavirin combination therapy

Hcv Replication in Pbmc and Its Influence on Interferon Therapy

Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C

Influence of Variations in Hepatitis B Virus Genome on the Response to Interferon Therapy

What are the limits of efficacy for immunotherapy against hepatocellular carcinoma and its clinical availability

Evolutionary Study of Hepatitis C Virus Envelope Genes During Primary Infection.

Amino Acid Sequence Analysis in Patients with Chronic HCV Genotype 1b Infection During Pegylated Interferon-Α2a and Ribavirin Therapy.

Gene variation of 5′-NCR and core region in serum samples collected from patients with HCV infection

Variation of Hypervariable Regions of the Genome of Hepatitis C Virus in EBV Transforming PBMC from Patients with Hepatitis C

Primary Structure and Variability of Partial Nonstructural Gene 5 Region of Hepatitis G Virus.

[Naturally Occurring NS5B Variants Resistant to Non-Nucleoside or Nucleoside Polymerase Inhibitors among Treatment-Naïve Hepatitis C Patients in South China].

Multigene Tracking of Quasispecies in Viral Persistence and Clearance of Hepatitis C Virus.